Targeted Oncology21h
Sonodynamic Therapy Shows Promise for Glioblastoma Treatment
A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with ...
Study reveals activity of navtemadlin in glioblastoma, points to possible treatment improvements
Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, ...
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
The ReSPECT-LM single-dose escalation trial assessed the safety, tolerability, and potential efficacy of intrathecally administered Rhenium ( 186 Re) Obisbemeda in patients with leptomeningeal ...
Kaleido Scope1d
Osuka receives Uncle Kory Foundation grant
Satoru Osuka, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Neurosurgery, has been awarded a $50,000 seed grant from the Uncle Kory Foundation to support ...
Chimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma Patients
Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...
City News13d
University of Manitoba-led study improves understanding of fatal brain cancer
A new study from researchers at the University of Manitoba is shedding new light and providing new hope for those living with a rare and fatal brain cancer, the very disease that claimed the life of ...
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc.
Morningstar8d
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
TPI 287 has been well tolerated in over 350 patients to date, including in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of recurrent glioblastoma ...